Vincentage

Vincentage (Vincentage Pharma Co., Ltd.) is a clinical-stage biotech founded in 2021 and headquartered in Suzhou, China, developing novel small-molecule drugs for metabolic and cardiometabolic diseases including type 2 diabetes, obesity, and MASH. Its lead candidate is VCT220 (also known as CX11), an oral small-molecule GLP-1 receptor agonist; worldwide rights (excluding Greater China) to CX11 were acquired by Corxel Pharmaceuticals. Investors include IDG Capital, Everest VC, Shenzhen Capital Group, Galaxy Industry Group, and Kunshan Asia Aroma. Surfaced as a portfolio company of IDG Capital and added to the API Evangelist network for enrichment; as a drug-discovery pharmaceutical company it publishes no public API, developer portal, or technical artifacts.

Vincentage is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub
5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyHealthcareBiotechnologyPharmaceuticalsDrug DiscoveryMetabolic DiseaseGLP-1China

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 5.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/vincentage: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: vincentage
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/vincentage.png
name: Vincentage
description: Vincentage (Vincentage Pharma Co., Ltd.) is a clinical-stage biotech founded in 2021 and headquartered in Suzhou,
  China, developing novel small-molecule drugs for metabolic and cardiometabolic diseases including type 2 diabetes, obesity,
  and MASH. Its lead candidate is VCT220 (also known as CX11), an oral small-molecule GLP-1 receptor agonist; worldwide rights
  (excluding Greater China) to CX11 were acquired by Corxel Pharmaceuticals. Investors include IDG Capital, Everest VC, Shenzhen
  Capital Group, Galaxy Industry Group, and Kunshan Asia Aroma. Surfaced as a portfolio company of IDG Capital and added to
  the API Evangelist network for enrichment; as a drug-discovery pharmaceutical company it publishes no public API, developer
  portal, or technical artifacts.
url: https://raw.githubusercontent.com/api-evangelist/vincentage/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- idg-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Metabolic Disease
- GLP-1
- China
apis: []
common:
- type: Website
  url: https://www.vincentage.com/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 0
  pass: local-v1